Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013)

Bio-Techne's (TECH) quarterly Curent Deferred Tax Liability came in at $9.9 million in Q2 2013, down 30.14% year-on-year from $14.2 million in Q2 2012, and down 1.23% quarter-over-quarter from $10.1 million in Q1 2013.

Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013) Analysis & Trends

Bio-Techne's Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $9.9 million for Q2 2013.

  • On a quarterly basis, Curent Deferred Tax Liability fell 30.14% year-over-year to $9.9 million in Q2 2013; TTM through Jun 2013 was $9.9 million, a 30.14% decrease from a year earlier, with the FY2013 full-year figure at $9.9 million, down 30.14% from the prior year.
  • Curent Deferred Tax Liability slipped to $9.9 million in Q2 2013 per TECH's latest filing, from $10.1 million in the prior quarter.
  • Across five years, Curent Deferred Tax Liability topped out at $14.2 million in Q2 2012 and bottomed at $4.2 million in Q4 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Bio-Techne 11.23 Bn 11.02 Bn 208.29 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2013 9.94 Mn
Jun 30, 2013 9.94 Mn
Mar 31, 2013 10.07 Mn
Mar 31, 2013 10.07 Mn
Dec 31, 2012 4.21 Mn
Dec 31, 2012 4.21 Mn
Sep 30, 2012 6.17 Mn
Sep 30, 2012 6.17 Mn
Jun 30, 2012 14.23 Mn
Jun 30, 2012 14.23 Mn
Mar 31, 2012 4.26 Mn
Mar 31, 2012 4.26 Mn